On the other hand, pegvisomant has been demonstrated to effectively control IGF-I levels while improving glucose metabolism (39, 40), obstructive sleep apnea (41), and arrhythmiasin acromegaly patients (42), with neutral or potentially beneficial effects on cardiovascular outcomes (43). This evidence concerns the gene IGF1 and obstructive sleep apnea syndrome.